Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RHHBY Roche Holding Ltd

Market Closed 12-20 16:00:00 EST Delay

盘后34.50

+0.000.00%

16:03 EST

{"stockData":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":34.5,"timestamp":1734728400000,"preClose":34.24,"halted":0,"volume":1251350,"hourTrading":{"tag":"盘后","latestPrice":34.5,"preClose":34.5,"latestTime":"16:03 EST","volume":781,"amount":26960.690000000002,"timestamp":1734728580099},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Market Closed","change":0.26,"latestTime":"12-20 16:00:00 EST Delay","open":34.32,"high":34.67,"low":34.29,"amount":43204388.725499995,"amplitude":0.011098,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":34.24,"volumeRatio":0.8438209394297236},"requestUrl":"/m/hq/s/RHHBY","defaultTab":"news","newsList":[{"id":"2492234100","title":"Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492234100","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492234100?lang=en_us&edition=fundamental","pubTime":"2024-12-20 01:28","pubTimestamp":1734629291,"startTime":"0","endTime":"0","summary":"Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2024/12/Stock-Prothena-sampls-comp-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/12/Stock-Prothena-sampls-comp-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/prothena-stock-roche-parkinsons-drug/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["PRTA","03165","RHHBY","BK4139","BK4007"],"gpt_icon":0},{"id":"2492101245","title":"RBC sees justification for Prothena rebound after study miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2492101245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492101245?lang=en_us&edition=fundamental","pubTime":"2024-12-20 01:20","pubTimestamp":1734628832,"startTime":"0","endTime":"0","summary":"RBC Capital keeps a Sector Perform rating on Prothena (PRTA) after the company’s partner Roche (RHHBY) presented topline data from the Phase IIb PA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-sees-justification-for-prothena-rebound-after-study-miss?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-sees-justification-for-prothena-rebound-after-study-miss?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4139","BK4007","PRTA","03165","BK4207"],"gpt_icon":0},{"id":"2492174258","title":"SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2492174258","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492174258?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:45","pubTimestamp":1734615900,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced that it has completed enrolment and dosing in the phase III EMERGENE study evaluating its investigational gene therapy, SRP-9003  for treating limb-girdle muscular dystrophy  Type 2E/R4 .Data from the EMERGENE study is expected in the first half of 2025. If the data is positive, Sarepta intends to submit a regulatory filing seeking accelerated approval for SRP-9003 in the given indication before the end of next year.The primary endpoint of the study is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease.LGMD2E/R4 is an ultra-rare form of LGMD for which there is no treatment beyond symptom management. Patients suffering from this genetic disease exhibit neuromuscular symptoms, which include difficulty in running, jumping and climbing stairs, before the age of 10. Because of the lack of treatments, the disease often progresses to loss of mobility during the teenage years and is associated with early ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-finishes-enrolment-stage-study-134500600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","BK4585","IE00B2B36J28.USD","BK4007","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","SSI","CTMX","IE0002141913.USD","SRPT","BK4139","CSTL","IE00BJT1NW94.SGD","03165","BK4196"],"gpt_icon":0},{"id":"2492127445","title":"Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127445","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127445?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:05","pubTimestamp":1734613500,"startTime":"0","endTime":"0","summary":"Roche said a Parkinson's disease experimental drug missed its primary goal in a mid-stage trial, the second setback this week for candidate treatments for the neurodegenerative condition.The update from the Swiss pharmaceutical giant came after Belgian peer UCB said a similar drug candidate for Parkinson's developed jointly with Novartis failed to meet key goals in a clinical trial.Roche said Thursday that its drug candidate, prasinezumab, didn't delay progression of motor symptoms in the trial, which included early-stage Parkinson's patients, to an extent considered statistically significant.However, the company said the drug did show potential clinical efficacy, as well as positive trends on several other goals of the trial, and was well tolerated. Roche will continue to evaluate the data and work together with health authorities to decide on next steps, it said.\"We believe the consistent efficacy trends from the Phase IIb study of prasinezumab merit further exploration,\" Roche's Chi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007","SSI"],"gpt_icon":0},{"id":"2492147559","title":"Roche announces PADOVA study misses statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492147559?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:10","pubTimestamp":1734603057,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s disease, trea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-padova-study-misses-statistical-significance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-padova-study-misses-statistical-significance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2492143811","title":"Roche's Negative Parkinson Drug Results Don't Surprise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2492143811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492143811?lang=en_us&edition=fundamental","pubTime":"2024-12-19 16:10","pubTimestamp":1734595800,"startTime":"0","endTime":"0","summary":"0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2492118997","title":"Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2492118997","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492118997?lang=en_us&edition=fundamental","pubTime":"2024-12-18 22:07","pubTimestamp":1734530846,"startTime":"0","endTime":"0","summary":"Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2018/04/stock-Merck-03-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/04/stock-Merck-03-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/merck-weight-loss-drugs-hansoh-pharma-licensing-deal-glp-1/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["RHHBY","LU0106261372.USD","LU0208291251.USD","AZN","LU0354030511.USD","SG9999014898.SGD","BK4516","LU0058720904.USD","LU1280957306.USD","LU0094547139.USD","LU1291159041.SGD","LU1066053197.SGD","LU0306806265.USD","LU2089984988.USD","LU0417517546.SGD","LU2361044865.SGD","03165","LU0320765489.SGD","LU0985481810.HKD","PFE","LU1023059063.AUD","IE00B19Z3581.USD","MRK","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0882574139.USD","PFE.AU","LU1066051498.USD","LU2211815571.USD","SG9999015341.SGD","SGXZ51526630.SGD","LU0203347892.USD","LU0203345920.USD","LU0385154629.USD","LU2023250843.SGD","LU0321505439.SGD","LU1551013425.SGD","IE0009355771.USD","BK4007","IE00B4R5TH58.HKD","LU0265550359.USD","LU0320765059.SGD","LU0456855351.SGD","LU2265009873.SGD","VKTX","LLY","LU0170899867.USD","LU2237443382.USD","GB00BDT5M118.USD","GPCR"],"gpt_icon":1},{"id":"2492866626","title":"Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2492866626","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492866626?lang=en_us&edition=fundamental","pubTime":"2024-12-17 06:03","pubTimestamp":1734386580,"startTime":"0","endTime":"0","summary":"The end of Novo Nordisk's supply problems could bring new headaches for the rest of the pharmaceutical industry, which now has to consider what it means to outsource its manufacturing to a company that owns a major competitor.Novo says that it has regulatory clearance to buy three key manufacturing sites used to make drugs like Wegovy, its blockbuster obesity medicine. That could ease the supply shortages that have dogged the launch of Wegovy and its sister drug, the Type 2 diabetes treatment Ozempic. However, the acquisition of the sites is part of a larger deal that could bring a reordering of the pharmaceutical industry.When the dust has settled, Novo will own three highly specialized facilities formerly owned by Catalent that do the difficult, finicky work involved in the last steps of manufacturing Wegovy and similar drugs. Novo has said it will \"honour all customer obligations\" at those three sites.Lilly shares closed 1.3% lower at $779.02 on Monday. In an August earnings call, t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","IE00B19Z8W00.USD","CTLT","IE0002141913.USD","LU1061106388.HKD","LU1868836591.USD","LU1720051017.SGD","LU2468319806.SGD","LU1854103824.USD","SG9999001176.SGD","SG9999018857.SGD","LU0354030438.USD","IE00BJJMRZ35.SGD","TMO","LU0354030511.USD","LU1267930730.SGD","IE00BJLML261.HKD","LU0109391861.USD","LU1917777945.USD","LU2237443382.USD","LU2264538146.SGD","LU0011850046.USD","BK4548","LU1815333072.USD","IE0004445239.USD","LU0471298694.HKD","LU1633808545.USD","LU0320765059.SGD","RHHBY","BK4533","LU2360106947.USD","BK4007","LU2023250504.SGD","LU2041044095.USD","SG9999018865.SGD","LU1791710582.SGD","LU1057294990.SGD","LU1366192091.USD","LU2237443549.SGD","LU0094547139.USD","LU2237443622.USD","LU0122379950.USD","03165","LU2720916845.USD","LLY","LU0061474960.USD","LU1791710400.SGD","LU0234572021.USD","LU1551013342.USD","LU0238689110.USD"],"gpt_icon":1},{"id":"2492647708","title":"Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2492647708","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492647708?lang=en_us&edition=fundamental","pubTime":"2024-12-17 02:40","pubTimestamp":1734374400,"startTime":"0","endTime":"0","summary":"Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe  of the ophthalmology drug Vabysmo .The regulatory body approved Vabysmo PFS for use in the treatment of neovascular or ‘wet’ age-related macular degeneration , diabetic macular edema  and macular edema following retinal vein occlusion .In the past three months, shares of Roche have lost 9.1% compared with the industry’s 14.3% decline.The approval of the Vabysmo prefilled syringe in the EU offers a convenient way to administer this leading ophthalmology treatment for people with three of the most common causes of vision loss.These three conditions — nAMD , DME and RVO — affect more than 9 million people in the EU.The PFS delivers the same drug as the currently available 6.0 mg Vabysmo vials in an alternative, ready-to-use format.Per Roche, Vabysmo PFS will be the EU’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness.Over the pas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-gets-approval-vabysmo-pfs-184000806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","BK4550","LU0823416689.USD","BK4585","LU1066053197.SGD","LU1868836757.USD","LU1868837136.USD","LU1917777945.USD","GILD","LU0225284248.USD","LU0234570918.USD","LU1670711040.USD","LU0053666078.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4139","LU1670711123.USD","BK4211","IE0009355771.USD","LU0306807586.USD","LU1718418525.SGD","LU1074936037.SGD","LU1670710588.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","LU1032466523.USD","LU2087621335.USD","LU2360032135.SGD","LU0868494617.USD","BMY","LU2106854487.HKD","LU0985481810.HKD","LU1974910355.USD","PFS","03165","LU0109394709.USD","RHHBY","IE0002141913.USD","LU0225771236.USD","IE00BZ1G4Q59.USD","LU2362541513.USD","BK4559","REGN","LU2242646821.SGD","LU1868836914.USD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2491994316","title":"Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491994316","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491994316?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354059,"startTime":"0","endTime":"0","summary":"The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/weight-loss-drugs-eli-lilly-novo-nordisk/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0882574055.USD","LU0321505868.SGD","LU0672654240.SGD","LU1064131342.USD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","LU0097036916.USD","NVO","LU0354030511.USD","LU2237443978.SGD","BK4532","LU1894683264.USD","BK4139","LU2324357040.USD","BK4550","LU1804176565.USD","LU2237443382.USD","LU0868494617.USD","LU2264538146.SGD","SG9999014914.USD","IE00B19Z3581.USD","LU0882574139.USD","LU0306806265.USD","LU0320765059.SGD","LU1066051498.USD","LU2237443465.HKD","LU0689472784.USD","RHHBY","REGN","LU0109394709.USD","SGXZ99366536.SGD","PFE","PFE.AU","LU2023250504.SGD","IE00BK4W5L77.USD","LU1093756325.SGD","NVO.AU","LU0225771236.USD","GPCR","LU2237443549.SGD","LU1814569148.SGD","LU0006306889.USD","LU2211815571.USD","LU0471298777.SGD","03165","VKTX","SG9999014898.SGD","LLY","LU2602419157.SGD","AMGN"],"gpt_icon":1},{"id":"2491370859","title":"Swiss Equities an Overweight Pick Next Year -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2491370859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491370859?lang=en_us&edition=fundamental","pubTime":"2024-12-14 00:36","pubTimestamp":1734107760,"startTime":"0","endTime":"0","summary":"1636 GMT - Bank of America is overweight on Swiss equities for 2025 in part because the country is heavy on the bank's defensive sector picks of food and pharma, analysts say in a research note on European equity strategy. \"Owing to its defensive sector overweight, the Swiss market tends to outperform when global PMI momentum is negative, as we expect it to be for most of next year,\" BofA analysts say. Switzerland has underperformed the broader European market by 15% over the past two years, they note. Among Swiss large caps, food giant Nestle's shares are down more than 20% year-to-date, while pharma heavyweights Roche and Novartis have made just single-digit gains. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","NSRGY","NVS"],"gpt_icon":0},{"id":"2491537198","title":"Regeneron Down 15.5% Year to Date: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491537198","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491537198?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:09","pubTimestamp":1734098940,"startTime":"0","endTime":"0","summary":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.Regeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma  or R/R diffuse large B-cell lymphoma after two","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRL","BAYRY","REGN","SNY","FL","LU1974910355.USD","LU2362541513.USD","IE00BFXG1179.USD","LU2023250504.SGD","BK4530","LU0320765992.SGD","LU0823416689.USD","LU2106854487.HKD","BK4588","RHHBY","LU0289739699.SGD","LU0058720904.USD","LU0882574055.USD","BK4585","BK4121","LU2362540622.SGD","LU0114720955.EUR","BK4007","LU0109394709.USD","LU0889565916.HKD","LU0390134368.USD","LU2362541273.HKD","LU2468319806.SGD","LU1917777945.USD","03165","BK4139","LU0053666078.USD","LU2089984988.USD","BK4094"],"gpt_icon":0},{"id":"2490035813","title":"Genentech presents updated fixed-duration Columvi and Lunsumio data at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490035813","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490035813?lang=en_us&edition=fundamental","pubTime":"2024-12-10 08:40","pubTimestamp":1733791210,"startTime":"0","endTime":"0","summary":"The company states: “Genentech, a member of the Roche (RHHBY) Group, announced that new and updated data from its industry-leading CD20xCD3 T-cell-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-presents-updated-fixed-duration-columvi-and-lunsumio-data-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-presents-updated-fixed-duration-columvi-and-lunsumio-data-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","03165","BK4007","LU2463526074.USD","ASH","BK4109"],"gpt_icon":0},{"id":"2490708294","title":"Roche Holding AG Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2490708294","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490708294?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:16","pubTimestamp":1733764560,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  rose 0.1% to CHF257.20 Monday on what proved to be an overall negative trading session for the stock market, with the Swiss SMI Index  falling 0.2% to 11,761.72.This was the stock's third consecutive day of gains.Roche Holding AG closed CHF31.00 short of its 52-week high of CHF288.20, which the company achieved on September 2, 2024.Trading volume was 749,156, compared to the 50-day average trading volume of 1,083,204.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2490754647","title":"Roche says five-year results confirm Polivy combo as ‘new standard of care’","url":"https://stock-news.laohu8.com/highlight/detail?id=2490754647","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490754647?lang=en_us&edition=fundamental","pubTime":"2024-12-09 04:05","pubTimestamp":1733688313,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced data from a five-year follow-up of the pivotal Phase 3 POLARIX study evaluating Polivy in combination with MabThera/Rituxan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-says-five-year-results-confirm-polivy-combo-as-new-standard-of-care?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-says-five-year-results-confirm-polivy-combo-as-new-standard-of-care?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2489674932","title":"Stock Market Rallies On: AI Software, Biotechs, Costco Coming Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2489674932","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489674932?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:59","pubTimestamp":1733522386,"startTime":"0","endTime":"0","summary":"The stock market's holiday mood could continue in the coming week, as Oracle leads AI software names and Costco covers the retail angle.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2020/12/Stock-ChristmasTree-NYSE-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/12/Stock-ChristmasTree-NYSE-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/research/investing-action-plan/stock-market-ai-software-oracle-biotechs-costco-earnings/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["CASY","EME.AU","NVDY","LU1430594728.SGD","US30Y.BOND","ORCL","NVS","INCY","NVDS","LU0348825331.USD","US12M.BOND","NVD3.UK","TRV","NVD","US7Y.BOND","COST","AZO","RHHBY","BEAM","LU1334329650.SGD","US6M.BOND","LEN","NVD2.UK","TOL","LU1153585028.USD","US10Y.BOND","BLK.AU","US3Y.BOND","AMGN","NVDA","SNVD.UK","3NVD.UK","MDB","TCOM","ADBE","03165","NVDU","US2Y.BOND","NVDS.UK","GILD","2NVD.UK","NVDD","BLK","US5Y.BOND","EME","NVDX","LU0345768153.USD","UNFI"],"gpt_icon":1},{"id":"2489231752","title":"Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2489231752","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489231752?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:11","pubTimestamp":1733490660,"startTime":"0","endTime":"0","summary":"This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK candidate sacituzumab tirumotecan for a lung cancer indication and approved AstraZeneca’s AZN blockbuster cancer drug, Imfinzi for a new indication. The FDA also accepted Roche’s RHHBY supplemental filing seeking expanded use of its drug, Columvi. J&J JNJ also filed an application with the FDA, seeking approval of Tremfya for children.Here's a recap of the week’s most important stories.LLY’s Zepbound Outperforms NVO’s Wegovy in Weight Loss Study. The FDA granted approval to AstraZeneca’s Imfinzi for treating limited-stage small cell lung cancer , an aggressive form of lung cancer, in the United States. The approval was based on data from the ADRIATIC phase III study for LS-SCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-llys-zepbound-131100794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2602419157.SGD","LU1551013425.SGD","LU0965509283.SGD","LU1291159041.SGD","RHHBY","03165","JNJ","LU1941712264.USD","LU0345769128.USD","LU0795875169.SGD","LU2063271972.USD","LU0096364046.USD","LU0320765489.SGD","LU2491050154.USD","LU1261432733.SGD","LU0320765646.SGD","LU0122379950.USD","LU0820561909.HKD","LU1983299246.USD","SG9999018865.SGD","LU1551013342.USD","LU1221951046.USD","LU1934455277.USD","LU2237443382.USD","SG9999017495.SGD","LU0094547139.USD","IE00BK4W5L77.USD","MRK","LU0882574055.USD","IE00BJT1NW94.SGD","ADC","LU0861579265.USD","LU0889566641.SGD","IE00B19Z3581.USD","LU0109391861.USD","IE00BK4W5M84.HKD","LU1066051811.HKD","LU2462157665.USD","BK4533","AZN","LU1935042991.SGD","SG9999015945.SGD","LU1066051225.USD","LU1116320737.USD","LU1894683348.USD","SG9999001440.SGD","LLY","SG9999014575.USD","LU0203347892.USD","LU2237443622.USD"],"gpt_icon":1},{"id":"2489245032","title":"FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2489245032","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489245032?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:24","pubTimestamp":1733405040,"startTime":"0","endTime":"0","summary":"RocheRHHBY announced that the FDA has accepted its supplemental biologics license application  seeking expanded use of Columvi  for second-line relapsed or refractory (R/R) diffuse large B-cell lymphoma  for review. The eligible population includes DLBCL patients who have received at least one prior line of treatment  and are not candidates for autologous stem cell transplant. A final decision from the regulatory body is expected on July 20, 2025.The STARGLO study is designed as a confirmatory study to convert the accelerated approval of Columvi in the United States and conditional marketing authorization in the EU to full approvals for third-line R/R DLBCL. Roche is also currently evaluating Columvi in combination with Polivy , MabThera/Rituxan, cyclophosphamide, doxorubicin and prednisone in the phaseIII SKYGLO study to treat previou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-roches-columvi-sbla-132400754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","LU0109394709.USD","LU2468319806.SGD","LU1430594728.SGD","HALO","SGXZ57979304.SGD","IE00B3T34201.USD","BK4583","IE0002270589.USD","LU0321505439.SGD","SG9999001176.SGD","SG9999001176.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","LU0321505868.SGD","LU1894683264.USD","IE00B19Z3581.USD","03165","BK4566","PFE","BK4599","BK4592","BK4007","LU1883839398.USD","LU1023059063.AUD","LU0053671581.USD","BK4568","LU0306806265.USD","LU1585245621.USD","BK4533","LU0868494617.USD","RHHBY","LU0985481810.HKD","IE00BBT3K403.USD","LU2087621335.USD","LU0058720904.USD","SG9999011175.SGD","LU0225284248.USD","SG9999002224.SGD","SOC","IE00B7SZLL34.SGD","LU0234572021.USD","LU0289739699.SGD","GILD","LU1894683348.USD","BK4532","BK4585"],"gpt_icon":1},{"id":"2489443677","title":"Genentech announces FDA acceptance of Columvi combination sBLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2489443677","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489443677?lang=en_us&edition=fundamental","pubTime":"2024-12-05 18:30","pubTimestamp":1733394626,"startTime":"0","endTime":"0","summary":"Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, for Co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-announces-fda-acceptance-of-columvi-combination-sbla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-announces-fda-acceptance-of-columvi-combination-sbla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2488923421","title":"NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923421","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923421?lang=en_us&edition=fundamental","pubTime":"2024-12-03 22:56","pubTimestamp":1733237760,"startTime":"0","endTime":"0","summary":"Novocure LimitedNVCR announced meeting the primary endpoint of overall survival  in a late-stage study, which evaluated the use of Tumor Treating Fields  therapy concomitantly with chemotherapy regimen as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. Shares of the company gained 49% on Monday in response to the encouraging news.TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The phase III PANOVA-3 evaluated the efficacy and safety ofTTFields therapy in combination with standard-of-care  chemotherapy  to treat pancreatic cancer patients. The enrolled patient population was randomized equally into two arms to receive either the combo regimen or SoC chemotherapy alone  and followed for atleast 18 months.Pancreatic cancer is one of the deadliest cancers and the third leading cause of cancer-related deaths in the United States. While overall cancer rates remaining stable or declining, pancreatic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvcr-stock-ttfields-therapy-meets-145600302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4452.SGD","BK4578","BK4534","IE0002270589.USD","IE00BZ1G4Q59.USD","SG9999001176.SGD","BK4566","LU1894683348.USD","BK4532","GILD","SG9999002224.SGD","LU1571399168.USD","BK4007","SG9999011175.SGD","LU0889565916.HKD","LU1023059063.AUD","IE000M9KFDE8.USD","PFE","BK4533","LU0456855351.SGD","LU0058720904.USD","LU0109394709.USD","BK4550","LU1066051498.USD","NVCR","LU1839511570.USD","BK4548","03165","LU0985481810.HKD","RHHBY","LU2087621335.USD","LU0225284248.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","BK4139","LU2468319806.SGD","BK4581","IE00BSNM7G36.USD","SG9999002232.USD","LU0170899867.USD","LU1585245621.USD","OS","SG9999013999.USD","BK4592","LU1057294990.SGD","BK4097","BK4082","IE00BLSP4239.USD","LU0234570918.USD","BK4568"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.roche.com","stockEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":0.0654},{"period":"3month","weight":0.0843},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.22},{"period":"ytd","weight":0.1631}],"description":"Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at  transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.","exchange":"OTCQX","name":"Roche Holding Ltd","nameEN":"Roche Holding Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roche Holding Ltd,RHHBY,Roche Holding Ltd股票,Roche Holding Ltd股票老虎,Roche Holding Ltd股票老虎国际,Roche Holding Ltd行情,Roche Holding Ltd股票行情,Roche Holding Ltd股价,Roche Holding Ltd股市,Roche Holding Ltd股票价格,Roche Holding Ltd股票交易,Roche Holding Ltd股票购买,Roche Holding Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}